The ALVAC prime/ALVAC + AIDSVAX B/E boost RV144 vaccine trial induced an estimated 31% efficacy in a low-risk cohort where HIV 1 exposures were likely at mucosal surfaces. An immune correlates study demonstrated that antibodies targeting the V2 region and in a secondary analysis antibody-dependent cellular cytotoxicity (ADCC), in the presence of low envelope-specific (Env-specific) IgA, correlated with decreased risk of infection. Thus, understanding the B cell repertoires induced by this vaccine in systemic and mucosal compartments are key to understanding the potential protective mechanisms of this vaccine regimen. We immunized rhesus macaques with the ALVAC/AIDSVAX B/E gp120 vaccine regimen given in RV144, and then gave a boost 6 months later, after which the animals were necropsied. We isolated systemic and intestinal vaccine Env-specific memory B cells. Whereas Env-specific B cell clonal lineages were shared between spleen, draining inguinal, anterior pelvic, posterior pelvic, and periaortic lymph nodes, members of Env specific B cell clonal lineages were absent in the terminal ileum. Env specific antibodies were detectable in rectal fluids, suggesting that IgG antibodies present at mucosal sites were likely systemically produced and transported to intestinal mucosal sites.
Introduction
The RV144 trial demonstrated 60% efficacy against infection at 6 months (1) and 31% efficacy at 2 years (2) . An immune correlates analysis showed that decreased transmission risk correlated with high levels of plasma envelope-binding (Env-binding) antibodies against gp120 variable regions 1 and 2 (V1V2) (3) . Antibody-dependent cellular cytotoxicity-mediating (ADCC-mediating) antibody levels and tier 1 neutralizing antibodies directly correlated with decreased transmission risk in the presence of low Env IgA antibodies (3) . The IgA correlate of risk may have been due to specific Env-binding IgA antibodies
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blocking the activity of ADCC antibodies (4) . Moreover, plasma antibody binding to linear V2 and variable region 3 (V3) (5) as well as binding to V1V2 scaffold proteins from multiple HIV-1 isolates (6) also correlated with decreased infection risk. Higher IgG3 antibody responses against V1V2 have been suggested to be a primary effector IgG subclass (7) (8) (9) . Sequencing of the transmitted/founder viruses isolated from RV144 vaccinees that did become infected demonstrated the lysine at position 169 (K169) in the V2 region as a site of selection pressure (10) . Analyses of mAbs representative of the putative protective antibodies from RV144 subjects showed that the V2 K169-centered epitope is recognized by antibodies with restricted variable heavy (V H ) and variable light (V L ) chain gene usage (11) and that V L restriction for recognition of the V2 epitope around K169 is conserved throughout primate phylogeny (12) . Thus, the current hypothesis is that ADCC or other Fc receptor-mediated (FcR-mediated) anti-HIV-1 functions of V2 and other Env antibodies were the likely correlates of protection (7, (13) (14) (15) (16) .
The RV144 study did not include mucosal sampling, and therefore it has not been possible to test for the presence of antibodies at mucosal sites in vaccine recipients. Invasive sampling methods to obtain lymph nodes (LNs) or spleen tissues from vaccinees that can provide mechanistic insights into vaccine responses are logistically difficult or impossible in human populations. In order to perform a more detailed analysis of the antibody response to the RV144 vaccine, we undertook a study in rhesus macaques using the same vaccine regimen as that given to humans in RV144, performed LN and spleen sampling following the final immunization, and performed a memory B cell repertoire analysis to determine the specificity and location of RV144 vaccine-induced Env-reactive B cells.
Results
Epitope mapping of plasma antibody responses to RV144 vaccine Envs. Five rhesus macaques (RMs) were immunized with the vaccine regimen used in RV144 ( Figure 1A ). The immunogens were ALVAC-HIV (vCP1521), a recombinant canarypox expressing HIV-1 Gag and Pro from B.LAI and HIV-1 gp120 from CRF01_AE (92TH023) linked to the transmembrane anchoring portion of gp41 from B.LAI; and AIDS-VAX B/E, an alum-adjuvanted bivalent HIV-1 gp120 Env glycoprotein vaccine from strains E.A244 (E.CM244) and B.MN produced in Chinese hamster ovary cell lines. After receiving 2 immunizations of ALVAC-HIV alone, followed by 2 boosts with ALVAC-HIV with AIDSVAX B/E, the animals were subsequently boosted with ALVAC-HIV and AIDSVAX B/E at week 53, and 2 weeks later the animals were necropsied with extensive tissue sampling. Binding antigen multiplex assay (BAMA) (6) of the plasma demonstrated systemic antibody responses to the 3 Env isolates in the vaccine in all animals ( Figure 1 , G-I) as well as to the gp70 Case A2 V1V2 and C.1086 V1V2 tag proteins used in the RV144 correlates studies ( Figure 1 , J and K) (3, 6) . We also observed binding to a scaffolded version of the V1V2 loop of AE.A244 ( Figure 1L ). For all animals, high titers of antibodies were detected after the fourth immunization as well as after the final boost.
We tested for the ability of plasma antibody to block the binding to gp120 of key V2 (CH58, CH59, CH01) and C1 (A32) targeted mAbs, and soluble CD4 (sCD4; Figure 1 , B-F). As was observed in RV144 trial participants (17) , at the end of the first 4 immunizations all animals developed high levels of mAb A32-blocking antibodies ( Figure 1B ). In addition, we observed blocking of sCD4 ( Figure 1C ). We also observed blocking of V2 mAbs CH58 and CH59 (Figure 1 , D and E) and low-level blocking of the V2V3 broad neutralizing antibody (bnAb) CH01 (18) (Figure 1F ).
Functional activity of serum antibody responses to RV144 vaccine Envs. TZM-bl neutralization assays of serum demonstrated that all animals had neutralization activity against the clade B strain in the vaccine (B.MN.3, Figure 2B ) and 4 of 5 animals had activity against the clade CRF01_AE strain in the ALVAC prime (AE.92TH023.6, Figure 2A ). All animals had activity against heterologous isolates from clade B (B.SF162.LS, Figure 2C ) and clade C (C.MW695.26, Figure 2E ); 4 of 5 animals also developed activity against B.BaL.26 ( Figure 2D ). All animals had a decrease in neutralization activity immediately prior to the final boost and this activity was boosted against all tested strains except for animal 33-11 that did not boost neutralization against AE.92TH023.6 or B.BaL.26. These neutralization results are similar to those observed in serum from vaccinees in the RV144 trial (19) .
We tested for ADCC activity mediated by plasma antibodies against target cells coated with gp120s reflective of 3 virus strains in the vaccine. The animals had little or no activity detectable in the prebleed samples, and all animals had activity detected in samples taken 2 weeks after the fourth immunization (Figure 2, F-N) . Titration of plasma antibodies indicated high levels against all 3 strains (Figure 2 , F-H), while Five rhesus macaques (RMs) were immunized 5 times (blue arrows above timeline) and peripheral blood taken 7 times (red arrows), rectal antibody sampled 4 times (green arrows), and the animals necropsied 2 weeks after the final immunization (black arrow). Individual macaques are represented by the same symbols in all figures. In plots B-R, dotted vertical lines represent immunization time points. Plasma antibodies were tested for their ability to bind gp120AE.A244 in ELISA and block the binding of mAb A32 (B), soluble CD4 (sCD4) (C), mAb CH58 (D), mAb CH59 (E), and bnAb CH01 (F). Plasma antibody binding in ELISA (plotted as log 10 AUC) was measured for gp120 AE.A244 (G), gp120 B.MN (H), gp120 AE.92TH023 (I), Case A2 gp70 V1V2 (J), C.1086 V1V2 tags (K), and AE.A244 V1V2 tags (L) . Rectal antibody was sampled using a surgical sponge inserted into the rectum and then eluted. Binding was measured and specific activity was calculated as specific activity = (antibody binding units × dilution factor)/measured rectal IgG in μg/ml for binding to gp120 AE.A244 (M), gp120 B.MN (N), gp120 AE.92TH023 (O), Case A2 gp70 V1V2 (P), C.1086 V1V2 tags (Q), and AE.A244 V1V2 tags (R). RMs 22-11, 46-11, and 60-11 boosted rectal antibody with the final immunization; those animals were selected for B cell repertoire analysis. determination of peak activity showed variation among the 3 strains (Figure 2 , I-K). Calculation of the area under the curve for the titration showed that activity was highest against the AE.A244 strain ( Figure  2M ), except for RM 31-11, which had higher activity against B.MN ( Figure 2N ). These results are similar to those observed for human participants in the RV144 trial (17) .
Detection of mucosal antibodies in immunized RMs. Using surgical sponges, we sampled antibody present in the rectal mucosa at weeks 25 and 29, after the fourth immunization, and again at weeks 53 and 55, at the time of the final immunization and necropsy. The concentration of recovered IgG for each sample is shown in Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/jci.insight.88522DS1; . Plasma antibody-dependent cellular cytotoxicity (ADCC) activity was measured against gp120-coated targets for the AE.92TH023 (F, I, and L), AE.A244 (G, J, and M), and B.MN (H, K, and N). ADCC activity is shown as reciprocal ADCC titer (F-H), peak activity in the assay (I-K), and log AUC (L-N). All animals had a rise in functional antibodies following vaccination. ID50, inhibitory dilution 50%.
we recovered more than 0.085 μg/ml of IgG from all but 3 samples. Although there was not gross blood contamination of the specimens, we cannot rule out that blood may have contributed to detected antibody levels. After the fourth immunization, all animals had detectable IgG against gp120s reflective of the vaccine strains (Figure 1 , M-O) and AE.A244 V1V2 ( Figure 1R ). When we assayed for binding to Case A2 gp70 V1V2 and C.1086 V1V2 scaffolded protein, we found that 4 of 5 RMs had detectable rectal antibody, but that RM 31-11 did not ( Figure 1 , P and Q). Detectable antibodies declined for all antigens after a 6-month rest, falling below the limit of detection for most animals, despite all but 1 animal (RM 46-11) having an IgG concentration above the limit of detection. After the final boost, 3 animals with sufficient recovery of rectal IgG (RMs 22-11, 46-11, and 60-11) were found to have substantial boosting of rectal antibody (Figure 1 , M-R). In contrast with rectal antibody, plasma levels did not decline as substantially (Figure 1 , G-L), raising the hypothesis that local production of antibody may have produced at least some of the antibodies detected in rectal fluid.
Flow cytometric assessment of antigenspecific B cells from LN and spleen. To assess whether anatomic distribution of B cells was responsible for the differences observed between plasma and rectal fluid, we performed antigen-specific B cell sorting of tissues. RMs 22-11, 46-11, and 60-11 were selected for further study because these animals had boosted mucosal antibodies following the final immunization (Figure 1 , In mesenteric LN and terminal ileum, antigenspecific B cell frequencies were slightly higher for gp120 AE.A244 than they were for gp120 M.ConS .
M-R)
. At the week 55 necropsy, samples of peripheral blood mononuclear cells (PBMCs), spleen, inguinal LN, anterior pelvic LN, posterior pelvic LN, periaortic LN, mesenteric LN, and terminal ileum were taken and studied. Samples from each tissue were sorted using gp120 M.ConS , gp120 AE.A244 , and AE.A244 V1V2 tags (11) as previously described (17); Supplemental Table 2 shows the number of memory B cells that were analyzed for each sorted tissue and Figure 3A shows examples of the observed patterns for gp120 M.ConS binding to memory B cells, defined as CD3/14/16 − , CD20 + , and surface IgD − . We found that up to 3.3% of memory B cells bound to gp120 antigen-specific reagents with the highest frequencies being present in PBMCs, anterior and posterior pelvic LNs, and periaortic LNs ( Figure 3 , B and C). The lowest frequencies were found in mesenteric LN and terminal ileum samples (range 0.02%-0.23%). Immunizations in this study were administered in the quadriceps, and so it was notable that the frequency of antigen-specific B cells was lower in the putative draining LN site (inguinal) compared with PBMCs, pelvic LNs, and periaortic LNs ( Figure 3 , B and C).
Memory B cell repertoire analysis of LN and spleen from RV144 vaccine-immunized RMs. From sorted memory B cells, we isolated a total of 1,494 mAbs that were screened following transient transfection; 1,242 (83%) of transiently expressed mAbs were reactive with HIV-1 Env ( Figure 4A ). For RM 22-11, we isolated 76 mAbs from PBMCs only. For the other 2 RMs, we isolated mAbs from PBMCs, spleen, and inguinal, anterior pelvic, posterior pelvic, periaortic and mesenteric LNs and terminal ileum; from terminal ileum we isolated 8 mAbs from RM 46-11 of which 6 were Env reactive, but the single mAb isolated from terminal ileum from RM 60-11 was not Env reactive ( Figure 4A ). The paucity of Env-reactive B cells in terminal ileum was remarkable given the large number of memory B cells we interrogated from that tissue (Supplemental Table 2 ). The majority of mAbs were isolated from gp120 AE.A244 Env-sorted cells (Supplemental Table 3 ), although the recovery of Env-reactive mAbs was similar for gp120 M.ConS Env-sorted cells; cells sorted using AE.A244 V1V2 tags gave a much lower recovery. We found that Env-reactive antibodies from the RMs had similar isotype ( Figure For RMs 66-11 and 60-11, envelope-reactive (Env-reactive) mAbs were isolated from most tissue compartments. (B) The majority (95%) of isolated mAbs were of IgG isotype. (C) V H gene segment usage was similar among the RMs with the majority of mAbs using V H 1, V H 3, and V H 4. Overall, 55% of mAbs used lambda chains. For kappa chain-using mAbs, the majority used V κ 1/1D or V κ 2/2D (D); for lambda chain-using mAbs, the majority used V λ 1, V λ 2, or V λ 3 (E). Each animal had some Env-reactive mAbs that used V λ 3~17, the lambda chain associated with genetically conserved V1V2 responses. (F) Heavy chain (HC) mutation frequencies were similar among Env-reactive antibodies for all 3 RMs; the overall mean mutation frequency was 9.3%.
Isolated Ig genes were analyzed using a Bayesian method (20) . The estimated mutation frequency of the heavy chains (HCs) of Env-reactive mAbs was 9.3% ( Figure 4F ); this mutation frequency was higher than that observed for Env-reactive antibodies isolated from humans immunized 4 times in the GSK PRO HIV-002 trial (3.8%; ref. 21) or in the RV144 trial (2.4%; ref. 17) , or for influenza-reactive antibodies recovered from trivalent influenza vaccine recipients (5.8%; ref. 22) . To address the possibility that the final immunization induced more somatic hypermutation, we isolated an additional 168 Env-reactive mAbs from PBMCs taken at the week 25 bleed (78 from 22-11, 42 from 46-11, and 48 from 60-11). The mean mutation frequency of this group of mAbs was 5.1% (Supplemental Figure 1A) . Comparison of the mutation frequency of mAbs from the 2 time points for each animal was statistically significant (t test, P < 0.0001 for each animal). This degree of mutation is still higher than that observed in RV144, suggesting that there may be an overestimation of mutation frequency in these RMs, but that the final boost did contribute to additional somatic hypermutation.
Using the same tools, we found that 638 of 1,242 (51%) of Env-reactive antibodies were members of clonal lineages ranging from 2 to 10 members ( Figure 5A ). For analysis of HC complementarity-determining region 3 (HCDR3) length, we collapsed each clonal lineage so that it would be counted only once; the median HCDR3 length was 16 amino acids for all animals ( Figure 5B ). This median length was similar to that observed in the 2 HIV vaccine trials (16.5 (23) (24) (25) (26) (27) . Interestingly, while no antibodies with HCDR3 loops of 24 amino acids or fewer were found in the 2 human vaccine trials (17, 21) , in this study we found that 49 of 1,242 (3.9%) recovered antibodies had HCDR3 loops of that length. Interestingly, the distribution HCDR3 loops of mAbs isolated at week 25 (Supplemental Figure 1B) was not statistically different than the week 55 mAbs ( Figure 5B) , suggesting that the 6-month rest and fifth immunization did not preferentially expand B cell populations with long HCDR3 loops.
Tissue distribution of clonal lineages. From RM 22-11, all 8 clonal lineages were from PBMCs. Five 2-member lineages were directed against the V1V2 loop ( Figure 5C ), as was one 3-member clonal lineage. One of the 2-member V2-targeted lineages contained a phylogenetically conserved ED motif (12) (lineage DH587), had a 14-amino acid HCDR3, and used V H 3~SC11 and V λ 3~17 reflective of the putative protective IgG V2 antibodies seen in RV144 (3, 11) . Remarkably, one member of this lineage was IgG and the other IgA, suggesting that in RM 22-11 there was the potential for trafficking of both IgA (via polymeric Ig receptor) and IgG (via neonatal Fc receptor) Env-reactive antibodies to mucosal surfaces.
For RM 46-11 and RM 60-11, there were 66 and 50 lineages, respectively, that had exactly 2 members and the majority of these lineages had members that were found in different tissues (50 lineages for RM 46-11, 36 lineages for RM 60-11; Figure 5C ). Analysis of the tissue distribution of larger clonal lineages with 3 or more members demonstrated that most lineages shared members across tissue types (Figures 6  and 7) . As expected, membership in shared lineages paralleled the recovery of mAbs from tissue sites; the majority of mAbs derived from PBMCs, spleen, and inguinal LNs ( Figure 4A ), and 88 of 95 (93%) lineages had members from those tissues (Figures 6 and 7) . Only 15 of 95 (16%) of lineages shared members with mesenteric LNs and no shared lineage members were isolated from terminal ileum, suggesting that few vaccine-elicited B cells trafficked to those sites.
Interestingly, when we analyzed all clonal lineages with 2 or more members, we found that no single tissue compartment contained members of all clonal lineages (Table 1) . Cells from spleen contributed members to approximately two-thirds of lineages and PBMCs contributed to almost half of clonal lineages. These data indicate that studies sampling only peripheral blood may give an incomplete view of clonal lineages elicited by a vaccine in RMs.
RM mAbs with activities similar to that found in RV144. Assay of plasma from RV144 participants demonstrated neutralization and ADCC activities (3, 19) and that isolated mAbs recapitulated both activities (17, 19) . Of the clonal lineages described above, we selected 4 lineages distributed across multiple tissues that either neutralized HIV-1 or that bound to the surface of HIV-1-infected CD4 + T cells as required for ADCC, in order to compare these lineages to mAbs isolated from RV144 participants (11, 17, 19) and to determine their detailed binding and/or functional activities. The 8-member DH614 lineage was found in 5 different anatomic sites, and this lineage used the same lambda chain gene associated with recognition of K169 (12) . The unmutated common ancestor (UCA) of this lineage weakly bound the V1V2 tag AE.A244 protein at high antibody concentrations (data not shown) but did not neutralize ( Figure 8A ). The mature antibodies of this lineage very potently bound Env proteins and V1V2 tags, but these antibodies did not bind gp120 AE.703357 , an Env protein derived from one of the placebo group infections in the RV144 trial that has a glutamine at position 169 (Q169) (11) . All members of this lineage have the glutamic acid/aspartic acid (ED) motif described for other antibodies of this class (12) . All mature lineage members potently bound Env proteins and AE.CM235-infected cells; however, neutralization potency varied among the members ( Figure 8A ). In contrast, when tested for neutralization the mature members of the DH612 B cell lineage potently neutralized the clade B isolate B.MN.3 and more weakly neutralized the clade AE isolate AE.92TH023.6 ( Figure 8B ); these antibodies were not able to neutralize AE.427299.c12 or AE.CM244.ec1 (data not shown). Antibodies of this lineage bound to AE.CM235-infected target cells ( Figure 8B ). The 7-member DH612 lineage was distributed across 5 tissues and had a UCA that weakly bound to a V3 tag AE.A244 protein at high antibody concentrations (data not shown). The mature lineage members bound gp120 M.ConS in ELISA but did not bind a panel of clade AE proteins or V1V2 epitopes in ELISA ( Figure 8B ), suggesting they recognized a conformational epitope expressed on infected cells.
The 5-member DH613 lineage was found in 5 different anatomic sites, and similar to the DH612 lineage, the DH613 lineage UCA bound to gp120 M.ConS with an EC50 of 64 μg/ml but did not neutralize. The mature mAbs of this lineage potently bound both gp120 M.ConS and several clade AE gp120 proteins ( Figure 8C) ; however, this lineage bound more weakly to AE.CM235-infected target cells. This lineage potently neutralized AE.92TH023.6 while still neutralizing B.MN.3, and may be reflective of tier 1 neutralizing antibodies that correlated with decreased infection risk in RV144 (5). The DH612 and DH163 lineages were not directed against the V1V2 loop, and these data combined with the previously reported V1V2-directed mAbs (12) demonstrate that RMs are capable of mounting a multiple-epitope, cross-clade response to the ALVAC/AIDSVAX B/E regimen.
Epitope mapping of mAbs. We further analyzed DH614 B cell lineage V2 mAbs on a series of V1V2 peptides that contained amino acid mutations across the 22-amino acid sequence. All mAbs in this lineage were sensitive to mutations at K169 (Figure 9A) , consistent with the ED motif described above; these mAbs were sensitive to changes in H173 that was also identified as part of epitope for this class of antibodies (12) . CH58 is a human mAb derived from an RV144 trial participant (11) that was sensitive to changes at both K169 and H173, and also to changes at K168, K171, F176, Y177, K178, D180, and P183; the mAbs of the DH614 lineage showed sensitivity to all of these changes except P183, but the degree of sensitivity varied between members of this lineage ( Figure 9A ), demonstrating ongoing affinity changes. These mAbs were similar to 2 other V λ 3~17 antibodies that were not clonally related to each other or to any other mAb isolated ( Figure 9D ). These mAbs also had the conserved ED motif (12) , bound to the surface of AE.CM235-infected cells, and did not bind to the RV144 isolate AE.703357 that did not match the vaccine Env sequence at position 169.
The 4-member DH621 lineage was found in 3 anatomic sites and epitope mapping showed that this lineage was specific for V1V2 and potently bound to AE.CM235-infected cells, but the DH621 lineage had a different pattern of sensitivity to amino acid substitution ( Figure 9B ) compared with the DH614 lineage ( Figure 9A ). We also mapped 2 other V1V2 mAbs that were not members of clonal lineages (DH623, DH624) and an additional mAb (DH627) that was clonally related to the previously reported mAb 2554 (12) ( Figure 9C ); these mAbs also had different V2 reactive patterns compared with other V1V2 mAbs. Notably, DH624 displayed less sensitivity to mutation of H173 ( Figure 9C) ; all of these antibodies bound to AE.CM235-infected cells, suggesting that the diversity of V1V2 responses that we observed might provide overlapping coverage of this variable Env region.
Antibodies with long HCDR3 loops. As noted above, we found antibodies with HCDR3 loops longer than those isolated from human HIV-1 vaccine trials. Since a number of HIV-1 bnAbs have long HCDR3 loops, we sought to determine if these antibodies from RMs had characteristics suggestive that they might be Figure 6 , clonal lineages are displayed in vertical stripes; below the line is shown the heavy chain complementarity-determining region 3 (HCDR3) length as an integer below and the V H gene used by the lineage. Clonal lineage mAbs were IgG except for 1 IgA (orange tick) and 1 IgM (green tick). Lineages that used light chain lambda gene segment V λ 3~17 are indicated by a dagger ( †) symbol. Lineages with members that mapped to the V1V2 loop are shown by a red vertical line. Individual mAbs are shown by horizontal tick marks; the length of the tick mark is proportional to heavy chain mutation frequency. Antibodies that were negative for HIV-1 envelope reactivity in screening are shown in light blue. The stripe corresponding to lineage DH614 in Figures 8 and 9 is indicated. No clonal lineages had mAbs isolated from terminal ileum. LN, lymph node; PBMC, peripheral blood mononuclear cell.
precursors of bnAbs; we examined 8 of the 49 Env-reactive mAbs with HCDR3 loops of 24 or more amino acids ( Figure 9E ). These mAbs were isolated from multiple anatomic sites and displayed an array of binding patterns. While some of the antibodies were sensitive to the loss of the N332 glycosylation site, none of the mAbs displayed potent neutralization (data not shown); mAb DH606 neutralized AE.92TH023.6 with an EC50 of 3.9 μg/ml and B.MN.3 at 0.48 μg/ml. DH606 and 3 other mAbs bound to AE.CM235-infected cells, suggesting that some of these long HCDR3 mAbs may have been developing the ability to mediate anti-HIV-1 functions after the fifth boost.
Discussion
In this study we have probed the RM plasma response to the ALVAC/AIDSVAX B/E gp120 vaccine and the memory B cell repertoire found in circulation and in lymphoid and mucosal tissues. The RMs in this study all developed robust plasma responses following vaccination that were sustained during Figure 8. (B) Mature lineage DH621 mAbs were most sensitive to changes at K168, Q170, K171, H173, K178, and D180. Lineage members bound the surface of AE.CM235-infected target cells. Lineage characteristics: V H 5~117/J H 4, heavy chain (HC) complementarity-determining region 3 (HCDR3) length 13, mean HC mutation frequency 5.2%; V κ 2~73/J κ 4, CDR3 length 9, mean light chain (LC) mutation frequency 4.7%. (C) V1V2-specific mAbs that did not use V λ 3~17 showed different patterns of sensitivity to amino acid substitutions. DH623 showed significantly reduced binding only for changes at H173. DH624 was not sensitive to H173 changes but was sensitive to changes at K178, L179, and D180. DH627 was sensitive to changes at H173, L175, and K178. All 3 mAbs bound the surface of AE.CM235-infected target cells. (D) Two mAbs that did use V λ 3~17 did not bind to a gp120 from RV144 breakthrough strain AE.703357, but did bind to proteins and V1V2 proteins reflective of the vaccine, and also bound to AE.CM235-infected target cells. (E) Tested long HCDR3 mAbs showed 3 patterns of binding to gp120 constructs. DH605 and DH622 showed reduced binding to gp120 AE.A244 N259A/N301A/N332A. DH609 and DH611 were clonally related and showed reduced binding to gp120 AE.A244 Δ371I/P363N and gp120 C.YU2 D368R; DH607 did not bind clade AE proteins but was sensitive to gp120 C.YU2 D368R. DH606, DH608, and DH610 potently bound all tested variants of gp120 AE.A244 but differentially bound gp120 C.YU2 variants. The anatomic site of origin appears after the mAb name: BL, peripheral blood; SP, spleen; IN, inguinal lymph node (LN); AP, anterior pelvic LN; PP, posterior pelvic LN; PA, periaortic LN; MT, mesenteric LN; ND, not done; MFI, mean fluorescence intensity; UCA, unmutated common ancestor. the 30-week rest (Figure 1, G-L) , but interestingly the plasma blocking activity and neutralization waned more than overall binding activity, although both activities rose after the final boost to levels comparable to those observed after the first 4 immunizations (Figure 1 , B-F, and Figure 2 , A-E). While this waning could be partially explained by differences in assay sensitivity and detection limits, the observed differences in functional assays is also consistent with different kinetics for the components of this polyclonal vaccine response, as might be expected if they arise from different pools of B cells. As with the human RV144 trial (19) , neutralization breadth elicited by ALVAC/AIDSVAX immunization in RMs was modest, with titers similar between the fourth and fifth immunization time points (Figure 2, A-E) ; all animals also developed plasma antibodies that mediated ADCC after the fourth immunization (Figure 2, F-N) . We found evidence of systemic V1V2 antibodies (Figure 1 , J and K) of the type that correlated with decreased risk in the RV144 vaccine trial (3, 6) . All of these data suggest that the regimen in RMs elicited antibody levels and functions that were similar to those observed in the human trial.
We selected a subset of animals for a more detailed anatomic analysis, and found that antigenspecific B cells could be detected in all sampled tissues (Figure 3) . Specifically, we isolated B cells expressing V2 K169 antibodies that mediated tier 1 neutralization and bound infected cells, along with V3 and CD4 binding site-directed antibodies with specificities similar to those of antibodies isolated from RV144 participants (11, 17, 19) . Importantly, these antibodies circulated in inguinal and pelvic LNs and spleen but were not found in terminal ileum. However, IgG Env antibodies were found in rectal wash fluids, indicating that the antibodies likely were derived from plasma/tissue fluid antibodies that crossed the mucosal barrier rather than being produced locally by intestinal mucosal B cells. Prior work on intestinal biopsies from early HIV-1 infection patients found that gp120-reactive B cells were not present, but gp41-reactive B cells could be found that cross-react with intestinal microbiota-derived antigens (28) . The AIDSVAX B/E vaccine did not contain gp41 and the ALVAC component contained only the transmembrane anchoring portion of gp41, and so the lack of gp120-reactive B cells found in terminal ileum in the present study may be because the vaccine-elicited B cells could not home to those mucosa-associated lymphoid tissues or because cells that did home to those sites were short-lived. We did not directly sample either vagina or rectum; thus, we do not know if antibody-secreting cells were present at those sites, but the rectal antibody data (Figure 1 , M-R) do not suggest that long-lived plasma cells were present and secreting Env-specific antibodies prior to the final boost. These RMs were immunized in the quadriceps and so it was interesting that the likely draining LN site (inguinal LN) did not have the highest frequency of antigen-specific B cells. Both anterior and posterior pelvic LNs had frequencies of antigen-specific B cells similar to that of PBMCs ( Figure 3 , B and C), and it is possible that B cells in these LNs could be rapidly recruited to sites of sexual transmission of HIV-1 (vagina and rectum) at the time of exposure, but whether this would have an impact on infection risk is not known.
We were able to detect rectal fluid antibodies in all animals after the fourth immunization time point (week 26), but in most RMs these antibodies waned to below the limit of detection during the 30-week rest (Figure 1, M-R) . Immediately prior to necropsy after the final immunization, we did not detect rectal antibody in 2 of the 5 animals, despite those animals having detectable antibodies at earlier time points. The heterogeneity of rectal antibody responses and the profound waning observed may provide an insight into the modest protective efficacy observed in the RV144 trial.
In addition, data from this anatomic study suggest that examination of peripheral blood may give only a partial view of the richness of B cell responses to a vaccine. We observed that clonal lineages were shared among many tissues ( Figures 5C, 6 , and 7) but only ~45% of these lineages had members found in peripheral blood (Table 1) . Given recent work aimed at stimulating germline precursors of broadly neutralizing antibodies and quantifying those responses (29) (30) (31) , data from the present study suggest that sampling of blood alone may not be able to detect all vaccine-elicited responses.
In summary, these results show that the RV144 regimen in RMs elicited a response similar to that observed in humans, and that this response was epitopically diverse and anatomically distributed. Mucosal antibodies were present but waned over the 30-week rest, consistent with the decreasing protection observed in the human trial. Our results suggest that the RV144 regimen in humans likely did not induce antigen-specific B cell trafficking to intestinal mucosae.
Methods
Immunization of RM subjects. The vaccine regimen for this study is shown in Figure 1A . In short, ALVAC vCP1521 (5 × 10 7 PFU per dose) was administered in the quadriceps at weeks 0 and 4. Boosting immunizations of 5 × 10 7 PFU per dose ALVAC vCP1521 plus 600 μg per dose of AIDSVAX B/E gp120 were given at weeks 12, 23, and 53. Peripheral blood was obtained at each immunization and 2 weeks after each immunization. Rectal antibodies were sampled by a surgical sponge placed in the rectum at weeks 25, 29, 53, and 55. Two weeks after the week 53 boost, the animals were euthanized and peripheral blood, spleen, inguinal LN, anterior pelvic LN, posterior pelvic LN, periaortic LN, mesenteric LN, and terminal ileum were collected. Peripheral blood was processed for serum (coagulated blood) or plasma and PBMCs (anticoagulated blood); all samples were aliquoted and maintained at −80°C (serum/plasma) or in liquid nitrogen vapor phase (cells) for further analysis.
Single PCRa products were used as templates for nested PCR (PCRb). Each 50-μl reaction contained 3 μl PCRa product, 0.6 μl HotStar Taq (Qiagen), 5 μl PCR Buffer, 10 μl Q Buffer, 0.4 μl 25 mM dNTPs, 25 mM MgCl 2 (3 μl for IgH, 2 μl for Igκ/λ) and 0.125 μM IgH, IgK, or Igλ internal primers. PCRb reaction conditions were the same as for PCRa above. PCRb products were then analyzed by 1.2% SYBER Safe E-Gels (Invitrogen). Wells with bands indicating a PCR product were purified and sequenced. Sequencing results were analyzed by SoDA (33) and ARPP (20) software to infer VDJ arrangements.
Analysis of RM genes and clonal lineages was performed as described (12, 20, 34) . Clonal lineage membership was determined using Cloanalyst (20, 34, 35) .
Recombinant mAb expression. For high-throughput characterization of isolated mAbs, transient transfection was performed as previously described (12, 32) . To produce the transfection construct, 2 μl V H /V L PCRb product, 1 μl KOD polymerase (Novagen), 5 μl KOD buffer, 5 μl dNTPs, 3 μl 25 mM MgSO 4 , 1 μl CMV-262, 1 μl 1822BGH (IgH) or BGH-1235 (IgK/λ), 2 μl rhesus CMV_P DNA fragments, 2 μl reversed DNA primers for either IgH or IgK/λ were brought to 50 μl with H 2 O. PCR conditions were as follows: 95°C/2 minutes, (95°C/20 seconds, 62°C/12 seconds, 70°C/60 seconds) for 30 cycles, then hold at 4°C. PCR products were purified by MinElute 96UF plates and analyzed by QIAxcel (Qiagen) before transient transfection.
Transient transfection was performed using 293T cells cultured in 6-well plates. Approximately 1 μg of heavy and light chain recombinant linear fragments was cotransfected by Effectene (Qiagen) when cells cultured in 10% FBS supplemented DMEM were 80%-90% confluent. Cell medium was changed to 2% FBS/DMEM before adding the transfection mixture. After 3 days of incubation at 37°C/5% CO 2 , supernatants were harvested for analysis. genotype for Fcγ receptor IIIa were used as the source of effector cells. CD4 + T cells were activated and infected with AE.CM235 as described (43) , and binding to AE.CM235-infected target cells was determined by indirect surface immunofluorescence analysis as described (44) .
Statistics. Four-parameter logistic regression and determination of the half maximal binding concentration (EC50) of mAbs in ELISA was performed using the drc package in R (45) . Other statistical tests were performed in SAS v9.4; the test is noted where P values are shown. A P value of less than 0.05 was considered significant.
Study approval. All RMs were housed at the New England Primate Research Center, Southborough, Massachusetts, USA and treated in accordance with the regulation of Association for Assessment and Accreditation of Laboratory Animals with the approval of the Animal Care and Use Committees of the NIH and Harvard Medical School.
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